A 24-week, randomised, open-label, parallel-group, multi-centre study which compares the efficacy and safety of rosuvastatin 10, 20 and 40 mg with atorvastatin 10, 20 40 and 80 mg when force titrated in the treatment of patients with primary hypercholesterolemia and either a history of coronary heart disease (CHD) or clinical evidence of atherosclerosis or a CHD risk equivalent (10 year risk score >20%).

Study identifier:4522IL/0101

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 24-week, randomised, open-label, parallel-group, multi-centre study which compares the efficacy and safety of rosuvastatin 10, 20 and 40 mg with atorvastatin 10, 20 40 and 80 mg when force titrated in the treatment of patients with primary hypercholesterolemia and either a history of coronary heart disease (CHD) or clinical evidence of atherosclerosis or a CHD risk equivalent (10 year risk score >20%).

Medical condition

hypercholesterolaemia

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria